EUROPEAN NEUROPSYCHOPHARMACOLOGY

Scope & Guideline

Transforming Understanding into Patient Care

Introduction

Immerse yourself in the scholarly insights of EUROPEAN NEUROPSYCHOPHARMACOLOGY with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN0924-977x
PublisherELSEVIER
Support Open AccessNo
CountryNetherlands
TypeJournal
Convergefrom 1990 to 2024
AbbreviationEUR NEUROPSYCHOPHARM / Eur. Neuropsychopharmacol.
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressRADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS

Aims and Scopes

The journal 'European Neuropsychopharmacology' focuses on the intricate relationships between neuroscience, pharmacology, and psychiatric disorders, aiming to advance knowledge in the field through rigorous research and innovative methodologies.
  1. Neuropsychopharmacology:
    The core focus of the journal is on neuropsychopharmacology, examining how drugs affect the brain and behavior, and exploring new pharmacological treatments for various psychiatric disorders.
  2. Biomarkers and Diagnostics:
    Research related to biomarkers for psychiatric conditions is prevalent, aiming to identify biological indicators that can aid in the diagnosis and treatment of mental health disorders.
  3. Clinical Trials and Treatment Efficacy:
    The journal places significant emphasis on clinical trials assessing the efficacy and safety of psychiatric medications, including novel treatments and repurposed drugs.
  4. Genetics and Epigenetics:
    There is a consistent focus on the genetic and epigenetic factors influencing psychiatric disorders, including the use of polygenic risk scores and genome-wide association studies.
  5. Translational Research:
    The journal encourages translational research that bridges the gap between laboratory findings and clinical applications, aiming to improve treatment strategies for mental health disorders.
  6. Neuroimaging and Brain Function:
    Neuroimaging studies are a key component, investigating brain structure and function in relation to psychiatric symptoms and treatment outcomes.
  7. Psychiatric Comorbidities:
    The exploration of comorbidities among psychiatric disorders, particularly how they interact with physical health and treatment responses, is a notable area of interest.
The journal has seen a rise in interest in several emerging themes, reflecting the evolving landscape of psychiatric research and treatment methodologies.
  1. Psychedelic Research:
    There is a growing body of research focusing on the therapeutic potential of psychedelics for various psychiatric conditions, including depression and anxiety, indicating a shift towards exploring alternative treatment modalities.
  2. Digital Psychiatry and Telehealth:
    The COVID-19 pandemic has accelerated interest in digital psychiatry, including telehealth solutions and mobile health applications, to enhance patient care and monitoring.
  3. Integrative Approaches to Mental Health:
    Emerging themes include integrative approaches that combine pharmacotherapy with psychotherapy, lifestyle interventions, and digital tools to enhance treatment outcomes.
  4. Neuroinflammation and Immune Response:
    Research exploring the links between neuroinflammation, immune responses, and psychiatric disorders is gaining momentum, highlighting the biological underpinnings of mental health conditions.
  5. Precision Psychiatry:
    An increasing focus on precision psychiatry, utilizing genetic, epigenetic, and environmental factors to tailor treatments to individual patients, is becoming prominent in published studies.
  6. Machine Learning and AI in Psychiatry:
    The application of machine learning and artificial intelligence in predicting treatment responses and understanding psychiatric disorders is an emerging trend, showcasing the integration of technology in mental health research.
  7. Gut-Brain Axis Research:
    Research into the gut-brain axis and its implications for mental health is rapidly expanding, with studies examining how gut microbiota influence psychiatric symptoms and treatment outcomes.

Declining or Waning

While the journal has evolved over time, certain themes have shown a decline in prominence, reflecting shifts in research interests and funding priorities.
  1. Traditional Pharmacotherapy:
    There appears to be a waning interest in traditional pharmacotherapy approaches, as newer and more innovative treatments, including psychedelic therapies and neuromodulation techniques, gain traction.
  2. Single-Disease Focus:
    Research focusing exclusively on single disease models is declining, with more studies adopting transdiagnostic approaches that consider overlapping symptoms and shared biological mechanisms.
  3. Basic Science without Clinical Application:
    There is a noticeable decrease in studies that focus solely on basic science without clear clinical applications, as the journal increasingly prioritizes research with direct implications for patient care.
  4. Longitudinal Studies without Genetic Components:
    Longitudinal studies that do not incorporate genetic or epigenetic analyses are becoming less common, as the integration of these factors is essential for understanding complex psychiatric disorders.

Similar Journals

PSYCHIATRIC QUARTERLY

Elevating Clinical Insights in Psychiatry and Mental Health
Publisher: SPRINGERISSN: 0033-2720Frequency: 4 issues/year

PSYCHIATRIC QUARTERLY, published by Springer, stands as a pivotal resource in the field of psychiatry and mental health since its inception in 1927. With a reputable Q2 categorization in Psychiatry and Mental Health for 2023, this journal ranks impressively at #77 out of 567 in Scopus, placing it in the top 86th percentile of its category. Covering a diverse range of topics related to mental health, PSYCHIATRIC QUARTERLY aims to disseminate rigorous research findings, theoretical advancements, and clinical insights that contribute to improved mental health practices and policies. Although it does not offer open access, it provides substantial value to researchers, professionals, and students through its comprehensive analyses and scholarly articles. Located in New York, United States, the journal serves as an essential platform for advancing the understanding and treatment of psychiatric disorders, making it an invaluable addition to any academic library or research portfolio.

NERVENARZT

Transforming Psychiatric Care with Cutting-Edge Research
Publisher: SPRINGERISSN: 0028-2804Frequency: 12 issues/year

NERVENARZT, published by Springer, has established itself as a significant platform in the fields of Medicine, Neurology, and Psychiatry since its inception in 1947. With a focus on a wide array of topics in neurological and psychiatric health, the journal plays a crucial role in disseminating cutting-edge research and clinical insights that enhance understanding and treatment of neurological disorders. The journal is currently positioned in the Q3 category across various fields, reflecting its role in the academic community, and provides valuable contributions to both the clinical and theoretical aspects of neurology and psychiatry. While it does not offer open access options, NERVENARZT continues to make significant strides in literature with its comprehensive articles and research findings, aimed at researchers, healthcare professionals, and students interested in the latest developments in the neuroscience and mental health landscapes. Operating under rigorous academic standards, it holds respected rankings with Scopus, further underscoring its commitment to impactful scholarship through the years.

Psychiatry International

Connecting minds through groundbreaking research.
Publisher: MDPIISSN: Frequency: 4 issues/year

Psychiatry International, published by MDPI, is a dynamic and open-access journal dedicated to advancing the field of psychiatry and mental health. Since its inception in 2020, this journal has emerged as a vital platform for the dissemination of innovative research and impactful insights across various subdisciplines, encompassing psychiatric nursing, general medicine, and neuroscience. With an E-ISSN of 2673-5318, Psychiatry International facilitates accessibility to research findings and fosters collaboration among researchers, healthcare professionals, and academics worldwide. The journal's alignment with modern Open Access principles reflects its commitment to enhancing the visibility and reach of psychiatric research. Despite being relatively new, it has demonstrated a promising standing in Scopus rankings, positioning itself within the top quartile for Nursing (Psychiatric Mental Health) and showing potential for growth in other related categories. By encouraging submissions that address the latest developments and challenges in mental health, Psychiatry International aims to catalyze progress in mental health awareness and intervention strategies, making it an essential resource for anyone engaged in the field.

BEHAVIOURAL PHARMACOLOGY

Bridging Psychiatry and Pharmacology for Better Outcomes
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0955-8810Frequency: 8 issues/year

Behavioural Pharmacology is a distinguished academic journal published by Lippincott Williams & Wilkins, focusing on the intricate relationship between pharmacology, psychiatry, and behavioral science. With an ISSN of 0955-8810 and an E-ISSN of 1473-5849, this journal serves as a vital platform for researchers and professionals dedicated to exploring the pharmacological mechanisms underlying behavior and mental health. Operating with a robust track record since its inception in 1992, it has established itself in the academic community, as reflected by its Q3 rankings in both the pharmacology and psychiatry categories for 2023. Additionally, the journal holds a credible position in Scopus rankings, with a percentile ranking indicative of significant contributions to the fields of pharmacology and psychiatry. Aimed at advancing knowledge and disseminating research in the behavioral pharmacology domain, this journal is an essential resource for students, researchers, and clinical professionals seeking to stay at the forefront of this rapidly evolving field. While it is not an open access journal, the rich content and research findings published here continue to foster collaboration and innovation within the community, making it a crucial reference point for current and future studies.

Biological Psychiatry

Unraveling the complexities of psychiatric disorders through biology.
Publisher: ELSEVIER SCIENCE INCISSN: 0006-3223Frequency: 24 issues/year

Biological Psychiatry is a premier journal dedicated to advancing the understanding of the biological underpinnings of psychiatric disorders. Published by Elsevier Science Inc, this esteemed journal is recognized globally for its rigorous peer-reviewed research and contributes significantly to the field of biological psychiatry. With an impressive impact factor that places it in Q1 of its category and ranks 3rd out of 51 in Neuroscience Biological Psychiatry, it reflects the journal's strength in disseminating high-quality findings that push the boundaries of knowledge. Since its inception in 1969, the journal has undergone continuous evolution, aiming to integrate biological and clinical perspectives to optimize the understanding of mental health conditions. Although it does not offer open access, Biological Psychiatry serves as a critical resource for researchers, practitioners, and students, offering insights that influence both theoretical frameworks and practical applications in the realm of psychiatric science.

PSYCHIATRIC GENETICS

Advancing Insights into Psychiatric Disorders through Genetics
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 0955-8829Frequency: 6 issues/year

PSYCHIATRIC GENETICS, published by LIPPINCOTT WILLIAMS & WILKINS, is a pivotal journal dedicated to the interdisciplinary study of genetic factors in psychiatric disorders, bridging the fields of genetics, psychiatry, and neuroscience. With a commitment to advancing research from its inception in 1990 and continuing through 2024, the journal provides a platform for innovative studies and findings that explore the genetic underpinnings of mental health. Although not currently an Open Access publication, it reaches a wide audience concerned with the complex interplay between genetics and psychiatric conditions, contributing to its Q3 and Q2 quartile rankings across multiple relevant categories in 2023. The importance of this journal cannot be understated; it serves as a crucial resource for researchers, clinicians, and students eager to uncover insights that could lead to more effective interventions and treatments in the realm of mental health.

Archives of Neuroscience

Unlocking the mysteries of the brain, one study at a time.
Publisher: BRIEFLANDISSN: 2322-3944Frequency: 4 issues/year

Archives of Neuroscience is a multidisciplinary journal dedicated to advancing the field of neuroscience through the publication of original research articles, review papers, and case studies. Published by BRIEFLAND, this journal aims to bridge the gap between neuroscience research and clinical applications, fostering a deeper understanding of brain function, neurological disorders, and potential therapeutic approaches. With an ISSN of 2322-3944 and an E-ISSN of 2322-5769, Archives of Neuroscience serves as an essential platform for researchers, professionals, and students alike, encouraging open access to knowledge and insights that drive innovation in the field. Although coverage was discontinued in Scopus from 2016 to 2017, the journal continues to uphold rigorous standards of academic excellence, making it a valuable resource for the neuroscience community seeking to explore and disseminate new findings. The journal is committed to providing timely access to research tools and findings that are crucial for informed decision-making in both academic and clinical settings.

INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Illuminating the path to better psychiatric therapies.
Publisher: OXFORD UNIV PRESSISSN: 1461-1457Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, published by OXFORD UNIV PRESS, is a leading open-access journal in the fields of pharmacology and psychiatry, with an impressive impact factor reflecting its prominence in academic research. Since its inception in 1998, the journal has provided a crucial platform for the publication of high-quality research, offering insights into the effects of neuropharmacological agents on mental health. As of 2023, it ranks in the Q1 category for both Pharmacology and Psychiatry & Mental Health, underscoring its relevance and authority within the scientific community. With notable rankings in various medical subspecialties, it attracts contributions that advance our understanding of psychiatric disorders and therapeutic strategies. The accessible nature of the journal, following its transition to open access in 2015, has expanded its reach, making knowledge and findings readily available to researchers, professionals, and students globally. This commitment to disseminating impactful research ensures the journal remains at the forefront of neuropsychopharmacological advancements.

Biological Psychiatry-Cognitive Neuroscience and Neuroimaging

Bridging Biological Psychiatry and Cognitive Neuroscience
Publisher: ELSEVIERISSN: 2451-9022Frequency: 12 issues/year

Biological Psychiatry-Cognitive Neuroscience and Neuroimaging is a leading interdisciplinary journal published by Elsevier, focusing on the convergence of biological psychiatry, cognitive neuroscience, and advanced neuroimaging techniques. With its prestigious Q1 rankings across essential categories such as Biological Psychiatry, Cognitive Neuroscience, and Neurology (clinical), this journal is at the forefront of research that examines the complexities of mental health through innovative methodologies. Covering a broad spectrum of topics from neurobiological mechanisms to clinical applications, it aims to provide a platform for scholars and practitioners to exchange insights on mental disorders and their neurobiological underpinnings. The impact factor and Scopus rankings further underscore its importance, with rankings highlighting its position in the top percentiles of related disciplines. By fostering an open exchange of ideas and promoting cutting-edge research, this journal is an essential resource for researchers, professionals, and students dedicated to advancements in the understanding and treatment of psychiatric and neurological conditions.

CORTEX

Fostering Interdisciplinary Collaboration in Neuroscience
Publisher: ELSEVIER MASSON, CORP OFFISSN: 0010-9452Frequency: 10 issues/year

CORTEX is a premier international journal published by Elsevier Masson, focusing on the cutting-edge areas of cognitive neuroscience, psychology, and neurology. With an impressive impact factor that places it in Q1 quartiles across multiple categories such as Cognitive Neuroscience and Neuropsychology, this journal serves as a vital resource for researchers, clinicians, and students alike. Established in 1964, CORTEX has continued to excel in disseminating high-quality scholarly work, offering insights that significantly enhance our understanding of the brain's functioning and behavior. Although not an open-access publication, it provides various access options to ensure the dissemination of knowledge is as wide-reaching as possible. As the field of cognitive psychology evolves, CORTEX remains at the forefront, fostering an environment for interdisciplinary collaboration and innovation. Researchers seeking to stay engaged with the latest advancements will find CORTEX an indispensable tool for their professional development.